» Articles » PMID: 35680690

The FOXO Family of Transcription Factors: Key Molecular Players in Gastric Cancer

Overview
Specialty General Medicine
Date 2022 Jun 10
PMID 35680690
Authors
Affiliations
Soon will be listed here.
Abstract

Gastric cancer (GC) is the fifth most frequently diagnosed cancer worldwide and the third leading cause of cancer-related death with an oncological origin. Despite its decline in incidence and mortality in recent years, GC remains a global public problem that seriously threatens patients' health and lives. The forkhead box O proteins (FOXOs) are a family of evolutionarily conserved transcription factors (TFs) with crucial roles in cell fate decisions. In mammals, the FOXO family consists of four members FOXO1, 3a, 4, and 6. FOXOs play crucial roles in a variety of biological processes, such as development, metabolism, and stem cell maintenance, by regulating the expression of their target genes in space and time. An accumulating amount of evidence has shown that the dysregulation of FOXOs is involved in GC progression by affecting multiple cellular processes, including proliferation, apoptosis, invasion, metastasis, cell cycle progression, carcinogenesis, and resistance to chemotherapeutic drugs. In this review, we systematically summarize the recent findings on the regulatory mechanisms of FOXO family expression and activity and elucidate its roles in GC progression. Moreover, we also highlight the clinical implications of FOXOs in GC treatment.

Citing Articles

FadA antigen of Fusobacterium nucleatum: implications for ceRNA network in colorectal cancer and adenomatous polyps progression.

Rezasoltani S, Shams E, Piroozkhah M, Aidi Y, Azizmohammad Looha M, Bagheri P Discov Oncol. 2025; 16(1):58.

PMID: 39826054 PMC: 11741970. DOI: 10.1007/s12672-025-01796-w.


Comprehensive Multi-Omics Analysis Reveals NPC2 and ITGAV Genes as Potential Prognostic Biomarkers in Gastrointestinal Cancers.

Piroozkhah M, Zabihi M, Jalali P, Salehi Z Cancer Rep (Hoboken). 2024; 7(12):e70087.

PMID: 39690926 PMC: 11652787. DOI: 10.1002/cnr2.70087.


Comprehensive analysis identifies endocrine fibroblast growth factors as promising prognostic markers for colorectal carcinoma.

Rejali L, Piroozkhah M, Jahanbin M, Jalali P, Khanabadi B, Abkenar E Sci Rep. 2024; 14(1):28754.

PMID: 39567612 PMC: 11579457. DOI: 10.1038/s41598-024-79341-y.


SIRT1 silencing ameliorates malignancy of non-small cell lung cancer via activating FOXO1.

Chen J, Chen K, Zhang S, Huang X Sci Rep. 2024; 14(1):19948.

PMID: 39198693 PMC: 11358480. DOI: 10.1038/s41598-024-70970-x.


mediated niche environment aberrations promote the progression of gastric cancer.

Yan T, Sun H, Liao Y, Zhou J Genes Dis. 2024; 11(5):101207.

PMID: 38882015 PMC: 11176646. DOI: 10.1016/j.gendis.2024.101207.


References
1.
Matsuzaki J, Tsugawa H, Suzuki H . Precision Medicine Approaches to Prevent Gastric Cancer. Gut Liver. 2020; 15(1):3-12. PMC: 7817924. DOI: 10.5009/gnl19257. View

2.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

3.
Liu Y, Ding W, Yu W, Zhang Y, Ao X, Wang J . Long non-coding RNAs: Biogenesis, functions, and clinical significance in gastric cancer. Mol Ther Oncolytics. 2021; 23:458-476. PMC: 8637188. DOI: 10.1016/j.omto.2021.11.005. View

4.
Usui G, Matsusaka K, Mano Y, Urabe M, Funata S, Fukayama M . DNA Methylation and Genetic Aberrations in Gastric Cancer. Digestion. 2020; 102(1):25-32. DOI: 10.1159/000511243. View

5.
Choi S, Jung S, Huh S, Chung Y, Cho H, Kang H . Alteration of DNA Methylation in Gastric Cancer with Chemotherapy. J Microbiol Biotechnol. 2017; 27(8):1367-1378. DOI: 10.4014/jmb.1704.04035. View